Possible Involvement of the Drug Transporters P Glycoprotein and Multidrug Resistance-Associated Protein Mrp2 in Disposition of Azithromycin

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 3, 2004, Pages 809-814

  Sugie, Masami ^a   Asakura, Emiko ^a   Zhao, Ying Lan ^a,d   Torita, Shoko ^a   Nadai, Masayuki ^b   Baba, Kenji ^c   Kitaichi, Kiyoyuki ^a   Takagi, Kenji ^a   Takagi, Kenzo ^a   Hasegawa, Takaaki ^a  

^a NAGOYA UNIVERSITY   (Japan)

^b MEIJO UNIVERSITY   (Japan)

^c AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CYCLOSPORIN; ERYTHROMYCIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 2; PROBENECID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG TRANSPORT; KIDNEY; KIDNEY CLEARANCE; LIVER; LUNG; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BILE; CYCLOSPORINE; ERYTHROMYCIN; HYPERBILIRUBINEMIA; IMMUNOSUPPRESSIVE AGENTS; INTESTINES; KIDNEY; LIVER; MALE; MITOCHONDRIAL PROTEINS; P-GLYCOPROTEIN; PROBENECID; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RENAL AGENTS; RIBOSOMAL PROTEINS; SACCHAROMYCES CEREVISIAE PROTEINS; TISSUE DISTRIBUTION;

EID: 10744233896     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.3.809-814.2004     Document Type: Article

References (39)

1. Amsden, G. W., A. N. Nafziger, G. Foulds, and L. J. Cabelus. 2000. A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers. J. CIin. Pharmacol. 40:1522-1527.
2. Ando, H., Y. Nishio, K. Ito, A. Nakao, L. Wang, Y. L. Zhao, K. Kitaichi, K. Takagi, and T. Hasegawa. 2001. Effect of endotoxin on P-glycoprotein-mediated biliary and renal excretion of rhodamine-123 in rats. Antimicrob. Agents Chemother. 45:3462-3467.
3. Asakura, E., H. Nakayama, M. Sugie, Y. L. Zhao, M. Nadai, K. Kitaichi, A. Shimizu, M. Miyoshi, K. Takagi, K. Takagi, and T. Hasegawa. Azithromycin reverses anticancer drug-resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur. J. Pharmacol., in press.
4. Borst, P., R. Evers, M. Kool, and J. Wijnholds. 1999. The multidrug resistance protein family. Biochim. Biophys. Acta 1461:347-357.
5. Carlier, M. B., I. Garcia-Luque, J. P. Montenez, P. M. Tulkens, and J. Piret. 1994. Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture. Int. J. Tissue React. 16:211-220.
6. Chen, Z. S., T. Kawabe, M. Ono, S. Aoki, T. Sumizawa, T. Furukawa, T. Uchiumi, M. Wada, M. Kuwano, and S. Akiyama. 1999. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol. Pharmacol. 56:1219-1228.
7. Foulds, G., R. M. Shepard, and R. B. Johnson. 1990. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 25:73-82.
8. Garey, K. W., C. A. Peloquin, P. G. Godo, A. N. Nafziger, and G. W. Amsden. 1999. Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, aclarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. Antimicrob. Agents Chemother. 43:1152-1155.
9. Gladue, R. P., G. M. Bright, R. E. Isaacson, and M. F. Newborg. 1989. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob. Agents Chemother. 33:277-282.
10. Gladue, R. P., and M. E., Snider. 1990. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob. Agents Chemother. 34: 1056-1060.
11. Gorski, J. C., D. R. Jones, B. D. Haehner-Daniels, M. A. Hamman, E. M. O'Mara, and S. D. Hall. 1998. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther. 64:133-143.
12. Gotoh, Y., H. Suzuki, S. Kinoshita, T. Hirohashi, Y. Kato, and Y. Sugiyama. 2000. Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. J. Pharmacol. Exp. Ther. 292:433-439.
13. Gottesman, M. M., I. Pastan, and S. V. Ambudkar. 1996. P-glycoprotein and multidrug resistance. Curr. Opin. Genet. Dev. 6:610-617.
14. Greenblatt, D. J., L. L. von Moltke, J. S. Harmatz, M. Counihan, J. A. Graf, A. L. Durol, P. Mertzanis, S. X. Duan, C. E. Wright, and R. I. Shatter. 1998. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin. Pharmacol. Ther. 64:278-285.
15. Kiso, S., S. H. Cal, K. Kitaichi, N. Furui, K. Takagi, K. Takagi, T. Nabeshima, and T. Hasegawa. 2000. Inhibitory effect of erythromycin on P-glycoprotein-mediated biliary excretion of doxorubicin in rats. Anticancer Res. 20:2827-2834.
16. König, J., A. T. Nies, Y. Cui, I. Leier, and D. Keppler. 1999. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461:377-394.
17. Kool, M., M. de Haas, G. L. Scheffer, R. J. Scheper, M. J. van Eijk, J. A. Juijin, F. Baas, and P. Borst. 1997. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57:3537-3547.
18. Masereeuw, R., F. G. Russel, and D. S. Miller. 1996. Multiple pathways of organic anion secretion in renal proximal tubule revealed confocal microscopy. Am. J. Physiol. 271:F1173-F1179.
19. Morris, D. L., A. de Souza, J. A. Jones, and W. E. Morgan. 1991. High and prolonged pulmonary tissue concentrations of azithroymycin following a single oral dose. Eur. J. Clin. Microbiol. Infect. Dis. 10:859-861.
20. Oude Elferink, R. P., D. K. Meijer, F. Kuipers, P. L. Jansen, A. K. Groen, and G. M. Groothuis. 1995. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. Biochim. Biophys. Acta 1241:215-268.
21. Periti, P., T. Mazzei, E. Mini, and A. Novelli. 1992. Pharmacokinetic drug interactions of macrolides. Clin. Pharmacokinet. 23:106-131.
22. Schinkel, A. H., U. Mayer, E. Wagenaar, C. A. Mol, L. van Deemter, J. J. Smith, M. A. van der Valk, A. C. Voordouw, H. Spits, O. van Tellingen, J. M. Zijlmans, W. E. Fibbe, and P. Borst. 1997. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA 94:4028-4033.
23. Schinkel, A. H., E. Wagenaar, C. A. Mol, and L. van Deemter. 1996. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Investig. 97: 2517-2524.
24. Schwab, J. C., Y. Cao, M. R. Slowik, and K. A. Joiner. 1994. Localization of azithromycin in Toxoplasma gondii-infected cells. Antimicrob. Agents Chemother. 38:1620-1627.
25. Seral, C., J. M., Michot, H. Chanteux, M. P., Mingeot-Leclercq, P. M., Tulkens, and F. van Bambeke. 2003. Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages. Antimicrob. Agents Chemother. 47:1047-1051.
26. Singlas, E. 1995. Clinical pharmacokinetics of azithromycin. Pathol. Biol. 43:505-511.
27. Takenaka, O., T. Horie, K. Kobayashi, H. Suzuki, and Y. Sugiyama. 1995. Kinetic analysis of hepatobiliary transport for conjugated metabolites in the perfused liver of mutant rats (EHBR) with hereditary conjugated hyperbilirubinemia. Pharm. Res. 12:1746-1755.
28. Taninaka, C., H. Ohtani, E. Hanada, H. Kotaki, H. Sato, and T. Iga. 2000. Determination of erythromycin, clarithromycin, roxithromycin, and azithromycin in plasma by high-performance liquid chromatography with amperometric detection. J. Chromatogr. B 738:405-411.
29. Terashita, S., T. Sawamoto, S. Deguchi, Y. Tokuma, and H. Hata. 1995. Sex-dependent and independent renal excretion of nilvadipine metabolites in rat: evidence for a sex-dependent active secretion in kidney. Xenobiotica 25:37-47.
30. Thiebaut, F., T. Tsuruo, H. Hamada, M. M. Gottesman, I. Pastan, and M. C. Willingham. 1987. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84:7735-7738.
31. Ueda, K., Y. Kato, K. Komatsu, and Y. Sugiyama. 2001. Inhibition of the biliary excretion of methotrexate by probenecid in rats: quantitative prediction of the interaction from in vitro data. J. Pharmacol. Exp. Ther. 297:1036-1043.
32. Ullrich, K. J., and G. Rumrich. 1997. Luminal transport step of para-aminohippurate (PAH): transport from PAH-loaded proximal tubular cells into the lumen of the rat kidney in vivo. Pflug. Arch. Eur. J. Physiol. 433:735-743.
33. Wacher, V. J., C. Y. Wu, and L. Z. Benet. 1995. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13:129-134.
34. Wakasugi, H., I. Yano, T. Ito, T. Hashida, T. Futami, R. Nohara, S. Sasayama, and K. Inui. 1998. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin. Pharmacol. Ther. 64:123-128.
35. Wang, L., K. Kitaichi, S. H. Cai, K. Takagi, K. Takagi, M. Sakai, L. Yokogawa, K. Miyamoto, and T. Hasegawa. 2000. Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo. Clin. Exp. Pharmacol. Physiol. 27:587-593.
36. Yamazaki, M., H. Suzuki, and Y. Sugiyama. 1996. Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm. Res. 13:497-513.
37. Yumoto, R., T. Murakami, Y. Nakamoto, R. Hasegawa, J. Nagai, and M. Takano. 1999. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J. Exp. Pharmacol. Ther. 289:149-155.
38. Zhao, Y. L., S. H. Cai, L. Wang, K. Kitaichi, Y. Tatsumi, M. Nadai, H. Yoshizumi, K. Takagi, and T. Hasegawa. 2002. Possible involvement of P-glycoprotein in the biliary excretion of grepafloxacin. Clin. Exp. Pharmacol. Physiol. 29:167-172.
39. Zhao, Y. L., X. B. Cen, M. Ito, K. Yokoyama, K. Takagi, K. Kitaichi, M. Nadai, M. Ohta, K. Takagi, and T. Hasegawa. 2002. Shiga-like toxin II derived from Escherichia coli 157:H7 modifies renal handling of levofloxacin in rats. Antimicrob. Agents Chemother. 46:1522-1528.